tislelizumab sold brand name tevimbra among others humanized monoclonal antibody directed prevents binding ligands hence checkpoint inhibitor designed bind less fc gamma developed beigene period celgene tislelizumab approved chinas national medical products administration phase trials began us australia june early results announced july phase ii clinical trial urothelial cancer started china phase iii trial multicenter phase iii trial advanced hepatocellular carcinoma started january phase clinical trial results give elimination halflife immune activation dostarlimab ibalizumab httpsenwikipediaorgwikitislelizumab